-
SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
B3C newswire
November 06, 2023
SOPHiA GENETICS (Nasdaq: SOPH), a category-defining software company and a global leader in data-driven medicine today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK).
-
BD to Showcase its Commitment to Drug Delivery and Packaging Innovation at CPhI 2023 Conference
B3C newswire
November 06, 2023
BD (Becton, Dickinson and Company), a leading global medical technology company, is excited to showcase at CPhI Barcelona 2023.
-
Vetter Looks Ahead to Further Expansions to Meet Supply Chain Demand
B3C newswire
November 06, 2023
Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), announces additional investments as part of its long-term dedication to customer partnerships.
-
Coriolis Pharma Announces Strategic Growth Partnership With KKR and Frontier Biosolutions
B3C newswire
November 06, 2023
Coriolis Pharma, a global service provider and a world leader in the formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines, today announced an investment from funds managed by KKR.
-
Atriva Therapeutics announces publication of Proof of Concept (POC) / Phase 2a RESPIRE study data with zapnometinib in patients hospitalized with COVID-19
B3C newswire
November 06, 2023
Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced today the publication of proof-of-concept data for its oral MEK inhibitor.
-
Sartorius Forms Partnership with SPARTA Biodiscovery on Novel Nanoparticle Analysis Platform
B3C newswire
November 06, 2023
The life science group Sartorius and UK-based startup SPARTA Biodiscovery have agreed to partner on SPARTA’s analysis platform.
-
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
B3C newswire
November 06, 2023
ProBioGen and GeoVax Labs, announce the signing of a landmark commercial license agreement for ProBioGen's groundbreaking AGE1.
-
Polpharma Biologics Announces Approval of Europe’s First and Only Biosimilar for Multiple Sclerosis - Tyruko® (Natalizumab)
B3C newswire
November 06, 2023
Polpharma Biologics, today announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe.
-
MC2 Therapeutics Acquires Option to Phase 2 Oral Drug Candidate for Hidradenitis Suppurativa and Other Indications
B3C newswire
November 06, 2023
MC2 Therapeutics announced today that it has acquired option rights from Regranion, LLC to exclusively license Regranion’s RGRN-305 for the treatment of all human diseases, incl, oral treatment of HS globally, excluding the greater China region.
-
Navigo Proteins and Nostrum Biodiscovery Announce a Research Collaboration to Enhance Affilin® Ligand Discovery Using Cutting-Edge AI and Molecular Modeling Techniques
B3C newswire
November 06, 2023
We are excited to announce a pioneering partnership between Nostrum Biodiscovery, a frontrunner in computational molecular engineering services, and Navigo Proteins, an innovator developing next generation targeting ligands called Affilin®.